A federally compliant cannabinoid drug developer says the DEA excluded it from the one hearing where its evidence mattered most, then watched the agency's own scientist testify to the very gap it wanted to address. MMJ International Holdings, Inc., along with its subsidiaries MMJ BioPharma Cultivation and MMJ BioPharma Labs, is now pressing that contradiction before the U.S. Court of Appeals for the District of Columbia Circuit, arguing it goes to the heart of whether the Attorney General's April 2026 Rescheduling Order can survive judicial review.
The dispute matters well beyond one company's appeal. State-licensed operators running seed-to-sale tracking systems, compliance logs, and inventory controls built around Schedule I status have a direct stake in how rescheduling proceeds procedurally, not just substantively. Retailers and multi-state operators watching this case unfold from the outside - the ones managing POS terminals, wholesale menus, and 280E tax exposure day to day - have their own compliance infrastructure to consider, and platforms like the Alaska dispensary POS platform illustrate how deeply state-level retail systems are already built around the current scheduling framework, regardless of what happens in federal court.
A Denial, Then a Contradiction Under Oath
DEA Administrator Terrance C. Cole signed the June 17, 2026 letter denying MMJ's request to participate in the rescheduling hearing, concluding the company's proposed testimony addressed legal rather than factual questions. Fair enough, on paper - DEA has discretion over who testifies and why. But weeks later, a DEA scientist from the agency's Scientific Review Division testified that state medical marijuana programs represent a significant source of diversion, and further acknowledged that diversion had not been analyzed in the 2023 Department of Health and Human Services scientific review underlying the rescheduling recommendation. That's not a minor technical aside. It's an admission that the administrative record DEA relied on had a hole in it, one MMJ says it was prepared to help fill before being turned away.
Why a Pharmaceutical Developer's Exclusion Carries Weight
MMJ's position in the rescheduling debate is unusual. Rather than operating through state commercial cannabis programs, the company has pursued FDA Investigational New Drug authorizations for Huntington's disease and multiple sclerosis programs, secured orphan-drug designation, and maintained a DEA-registered Schedule I analytical laboratory alongside a pending bulk-manufacturing registration application. That is a different regulatory lane entirely from retail dispensaries and adult-use supply chains, and it's precisely why MMJ argues its perspective on federal compliance gaps was relevant to the hearing record. "DEA told the one company that actually followed the federal drug approval process that it had nothing factual to contribute," said Duane Boise, CEO of MMJ International Holdings. "Then the government's own scientific witness testified about the very evidentiary gap we sought to address."
The Procedural Stakes Now Before the D.C. Circuit
MMJ's appeal challenges the Rescheduling Order on statutory grounds, including whether the Controlled Substances Act required formal rulemaking and whether the government could lawfully invoke treaty authority to bypass the procedures Congress established. The company points to the D.C. Circuit's decision in NORML v. DEA as limiting that treaty-authority argument. Whatever the court ultimately decides, the exclusion of a subpoenaed witness whose testimony might have addressed a documented gap in the scientific record is the kind of procedural detail appellate judges tend to take seriously - not because it changes the science, but because it changes whether the process itself held up.
What Operators Should Watch Next
None of this changes day-to-day compliance obligations for licensed dispensaries right now. Lab testing, COA requirements, compliant packaging, and age-verification rules remain governed by state law regardless of how the federal rescheduling appeal resolves. But a court ruling that unwinds or delays the Rescheduling Order on procedural grounds would ripple into banking access, 280E tax treatment, and interstate business planning for operators who had begun adjusting strategy around Schedule III status. MMJ's stay motion is fully briefed before the D.C. Circuit, and the outcome will shape how much weight future administrative hearings carry - and who gets to speak at them.